Maze Therapeutics' CEO will present at the J.P. Morgan Healthcare Conference on January 12, 2026, discussing its development pipeline.
Quiver AI Summary
Maze Therapeutics, Inc., a biopharmaceutical company focused on developing precision medicines for kidney and metabolic diseases, announced that CEO Jason Coloma, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will begin at 8:15 a.m. PT and will be available for live streaming on the company's website, with an archived version accessible for 30 days afterward. Maze Therapeutics uses human genetics to identify and develop novel small molecules, with its key projects including MZE829, an APOL1 inhibitor in Phase 2 for kidney disease, and MZE782, which targets phenylketonuria and chronic kidney disease. The company is based in South San Francisco.
Potential Positives
- Maze Therapeutics will present at the prestigious 44th Annual J.P. Morgan Healthcare Conference, highlighting its visibility and engagement with key stakeholders in the healthcare sector.
- The company’s presentation will be available via a live webcast, increasing accessibility for potential investors and interested parties.
- Maze Therapeutics is advancing promising drug candidates in its pipeline, such as MZE829 and MZE782, which have the potential to address significant health issues in kidney and metabolic diseases.
- The company utilizes a unique Compass™ platform to leverage human genetics for drug development, indicating a strong foundation in innovative research techniques.
Potential Negatives
- None
FAQ
What is Maze Therapeutics known for?
Maze Therapeutics develops small molecule precision medicines for patients with kidney and metabolic diseases.
When will Maze Therapeutics present at the J.P. Morgan Healthcare Conference?
Maze Therapeutics will present on January 12, 2026, at 8:15 a.m. PT.
Where can I watch the Maze Therapeutics presentation?
The presentation will be available via live webcast on the Investors section of the Maze Therapeutics website.
What pipeline candidates is Maze Therapeutics advancing?
Maze’s pipeline includes MZE829 for kidney disease and MZE782 for treating phenylketonuria and chronic kidney disease.
How can I contact Maze Therapeutics for more information?
You can contact Amy Bachrodt at [email protected] for investor inquiries or Amanda Lazaro at [email protected] for media inquiries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MAZE Insider Trading Activity
$MAZE insiders have traded $MAZE stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $MAZE stock by insiders over the last 6 months:
- ATUL DANDEKAR (CSBO) has made 0 purchases and 3 sales selling 72,500 shares for an estimated $2,940,799.
- HAROLD BERNSTEIN (President, R&D & CMO) has made 0 purchases and 2 sales selling 45,000 shares for an estimated $1,825,354.
- AMY BACHRODT (SVP, Finance) has made 0 purchases and 3 sales selling 15,000 shares for an estimated $606,173.
- RICHARD H SCHELLER sold 20,744 shares for an estimated $464,034
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MAZE Hedge Fund Activity
We have seen 61 institutional investors add shares of $MAZE stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FORESITE CAPITAL MANAGEMENT IV, LLC removed 1,589,262 shares (-75.3%) from their portfolio in Q3 2025, for an estimated $41,209,563
- VR ADVISER, LLC added 1,230,769 shares (+inf%) to their portfolio in Q3 2025, for an estimated $31,913,840
- VANGUARD GROUP INC added 915,342 shares (+218.1%) to their portfolio in Q3 2025, for an estimated $23,734,818
- MATRIX CAPITAL MANAGEMENT COMPANY, LP removed 832,500 shares (-33.5%) from their portfolio in Q3 2025, for an estimated $21,586,725
- MARSHALL WACE, LLP added 758,104 shares (+3868.5%) to their portfolio in Q3 2025, for an estimated $19,657,636
- BLACKROCK, INC. added 701,312 shares (+114.1%) to their portfolio in Q3 2025, for an estimated $18,185,020
- JANUS HENDERSON GROUP PLC removed 649,386 shares (-46.3%) from their portfolio in Q3 2025, for an estimated $16,838,578
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MAZE Analyst Ratings
Wall Street analysts have issued reports on $MAZE in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 12/04/2025
- Wedbush issued a "Outperform" rating on 11/07/2025
- JP Morgan issued a "Overweight" rating on 09/29/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/18/2025
- Guggenheim issued a "Buy" rating on 09/15/2025
- BTIG issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for $MAZE, check out Quiver Quantitative's $MAZE forecast page.
$MAZE Price Targets
Multiple analysts have issued price targets for $MAZE recently. We have seen 6 analysts offer price targets for $MAZE in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Sadia Rahman from Wells Fargo set a target price of $55.0 on 12/04/2025
- Ananda Ghosh from HC Wainwright & Co. set a target price of $60.0 on 12/03/2025
- Laura Chico from Wedbush set a target price of $36.0 on 11/07/2025
- Anupam Rama from JP Morgan set a target price of $37.0 on 09/29/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $34.0 on 09/15/2025
- Julian Harrison from BTIG set a target price of $37.0 on 09/12/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 30 days following the presentation.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com , or follow the company on LinkedIn and X .
IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
[email protected]
Media Contact:
Amanda Lazaro, 1AB Media
[email protected]
